{
    "name": "Gabapentin",
    "genericName": "Neurontin",
    "tags": [
        "gabapentinoid",
        "neuropathic pain",
        "anxiety",
        "alcohol withdrawal",
        "insomnia"
    ],
    "dosing": {
        "adult_acute": "300-3600 mg/day in divided doses",
        "adult_maintenance": "900-1800 mg/day (neuropathic pain); 300-900 mg/day (anxiety/insomnia off-label)",
        "notes": "Titrate based on tolerability. TID dosing recommended (short half-life). Antacids reduce absorption — separate by 2 hours. Off-label psychiatric use (anxiety, insomnia) common but limited evidence.",
        "canadian_clinical": {
            "starting_dose": "100-300 mg/day (start low for anxiety/insomnia); 300 mg TID for neuropathic pain.",
            "titration_schedule": "Increase by 300 mg every 1-3 days as tolerated.",
            "inpatient_strategy": "For alcohol withdrawal adjunct: 300 mg TID day 1, taper over 3-5 days. For pain: start 300 mg TID.",
            "outpatient_strategy": "Start low (100-300 mg nocte for insomnia). Titrate slowly. Avoid abrupt discontinuation.",
            "max_dose_evidence": "3600 mg/day (pain)",
            "max_dose_practice": "3600 mg/day (pain); 900-1800 mg/day (psychiatric off-label)."
        }
    },
    "cautions": {
        "renal": "Significant dose reduction required based on CrCl. Renally cleared — requires dose adjustment table.",
        "hepatic": "No specific adjustment needed.",
        "pregnancy": "Limited data; some neonatal concerns — use with caution."
    },
    "warnings": [
        "Sedation and dizziness — falls risk, especially in elderly",
        "Respiratory depression risk (especially with opioids, benzodiazepines, alcohol)",
        "Abuse potential (increasing recognition — schedule consideration in some provinces)",
        "Suicidal ideation (class warning for anticonvulsants)",
        "Abrupt withdrawal can cause seizures — taper gradually",
        "Peripheral edema",
        "Ataxia"
    ],
    "citations": [
        "NICE Neuropathic Pain CKS 2022",
        "Maudsley Prescribing Guidelines 14th ed",
        "CANMAT Anxiety Disorders 2014"
    ]
}
